Top Markets
Coin of the day
CTI BioPharma Corp. CTI BioPharma Corp.

CTI BioPharma Corp.

CTIC
Rang in Aktien #12591
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Aktienkurs
$9.09
Zuletzt synchronisiert: 2023-06-23
Marktkapitalisierung
$567.77M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel CTI BioPharma Corp. (CTIC)

Kategorie

Kursverlauf für CTI BioPharma Corp. (CTIC)
Höchster Schlusskurs: $9.07 am 2023-06-01

Niedrigster Schlusskurs: $121.75K am 1997-03-01
Kursverlauf der Aktie von CTI BioPharma Corp. von 1997 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 59.07%
2022 173.23%
2021 -38.21%
2020 161.00%
2019 5.88%
2018 -53.69%
2017 -42.12%
2016 -61.16%
2015 -49.72%
2014 27.27%
2013 38.57%
2012 -76.52%
2011 -49.34%
2010 -67.69%
2009 680.34%
2008 -99.33%
2007 -70.14%
2006 -20.03%
2005 -71.45%
2004 -4.83%
2003 6.48%
2002 -68.99%
2001 -35.93%
2000 997.50%
1999 22.69%
1998 -81.36%
1997 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.01 -13.08%
AU
$138.18 473.58%
US
$759.27 7.20%
CH